S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   418.64 (-1.13%)
AAPL   165.11 (-1.16%)
MSFT   399.83 (-1.10%)
META   486.23 (-3.10%)
GOOGL   154.10 (-1.22%)
AMZN   175.79 (-1.91%)
TSLA   149.46 (-0.31%)
NVDA   818.91 (-3.28%)
AMD   151.27 (-2.46%)
NIO   3.87 (-3.25%)
BABA   68.69 (-0.28%)
T   16.38 (+0.31%)
F   12.15 (+0.75%)
MU   109.57 (-2.11%)
GE   150.87 (-1.35%)
CGC   7.79 (-0.51%)
DIS   111.77 (-0.59%)
AMC   3.11 (+6.51%)
PFE   25.54 (+0.59%)
PYPL   61.95 (-0.24%)
XOM   120.64 (+1.79%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   418.64 (-1.13%)
AAPL   165.11 (-1.16%)
MSFT   399.83 (-1.10%)
META   486.23 (-3.10%)
GOOGL   154.10 (-1.22%)
AMZN   175.79 (-1.91%)
TSLA   149.46 (-0.31%)
NVDA   818.91 (-3.28%)
AMD   151.27 (-2.46%)
NIO   3.87 (-3.25%)
BABA   68.69 (-0.28%)
T   16.38 (+0.31%)
F   12.15 (+0.75%)
MU   109.57 (-2.11%)
GE   150.87 (-1.35%)
CGC   7.79 (-0.51%)
DIS   111.77 (-0.59%)
AMC   3.11 (+6.51%)
PFE   25.54 (+0.59%)
PYPL   61.95 (-0.24%)
XOM   120.64 (+1.79%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   418.64 (-1.13%)
AAPL   165.11 (-1.16%)
MSFT   399.83 (-1.10%)
META   486.23 (-3.10%)
GOOGL   154.10 (-1.22%)
AMZN   175.79 (-1.91%)
TSLA   149.46 (-0.31%)
NVDA   818.91 (-3.28%)
AMD   151.27 (-2.46%)
NIO   3.87 (-3.25%)
BABA   68.69 (-0.28%)
T   16.38 (+0.31%)
F   12.15 (+0.75%)
MU   109.57 (-2.11%)
GE   150.87 (-1.35%)
CGC   7.79 (-0.51%)
DIS   111.77 (-0.59%)
AMC   3.11 (+6.51%)
PFE   25.54 (+0.59%)
PYPL   61.95 (-0.24%)
XOM   120.64 (+1.79%)
S&P 500   4,998.76 (-0.25%)
DOW   37,959.42 (+0.49%)
QQQ   418.64 (-1.13%)
AAPL   165.11 (-1.16%)
MSFT   399.83 (-1.10%)
META   486.23 (-3.10%)
GOOGL   154.10 (-1.22%)
AMZN   175.79 (-1.91%)
TSLA   149.46 (-0.31%)
NVDA   818.91 (-3.28%)
AMD   151.27 (-2.46%)
NIO   3.87 (-3.25%)
BABA   68.69 (-0.28%)
T   16.38 (+0.31%)
F   12.15 (+0.75%)
MU   109.57 (-2.11%)
GE   150.87 (-1.35%)
CGC   7.79 (-0.51%)
DIS   111.77 (-0.59%)
AMC   3.11 (+6.51%)
PFE   25.54 (+0.59%)
PYPL   61.95 (-0.24%)
XOM   120.64 (+1.79%)
Free Trial
NASDAQ:CRME

Cardiome Pharma (CRME) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free CRME Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.30
▼
$2.45
50-Day Range
N/A
52-Week Range
$1.29
▼
$4.84
Volume
90,444 shs
Average Volume
135,322 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
CRME stock logo

About Cardiome Pharma Stock (NASDAQ:CRME)

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

CRME Stock News Headlines

August 13, 2023 | nasdaq.com
Amphastar Pharmaceuticals (FRA:29A) Price Target Increased by 46.10% to 60.45
March 25, 2023 | marketwatch.com
Expert Analysis on Pharmaceutical Rubber Stoppers Market by 2023-2030
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
February 17, 2023 | msn.com
Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg
February 12, 2023 | msn.com
Pharmacy Career Conference returned in its 4th edition to assist and inspire pharmacy students and industry professionals
February 1, 2023 | msn.com
Pharma sector growth healthy after Covid too
December 29, 2022 | cbsnews.com
DOJ sues pharma giant AmerisourceBergen Corp. for allegedly helping to fuel the opioid epidemic
November 2, 2022 | marketwatch.com
Acute Coronary Syndrome Therapeutics Market Size in Pharma & Healthcare Sector is Growing Quickly with Analysis by Top Key players till 2028
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
October 20, 2022 | yahoo.com
Pharmaceutical Fine Chemicals Category Is Projected to Grow at a CAGR of 5.86% by 2026, SpendEdge Reports
October 13, 2022 | finance.yahoo.com
Jenny Sundqvist new CEO of InDex Pharmaceuticals
September 28, 2022 | benzinga.com
1SOMAÍ Pharmaceuticals Opens Medical Cannabis Manufacturing Facility In Portugal
September 13, 2022 | msn.com
NLEM 2022 | Govt releases new list of 384 essential medicines; 34 drugs added, 26 dropped
September 13, 2022 | msn.com
Macleods Pharmaceuticals defers big-bang listing plans; will PE funds step in now?
August 30, 2022 | marketwatch.com
Cardiac Rhythm Management Devices Market [4.5% CAGR] 2022 Industry Research Analysis Opportunities Key Players Analysis And Forecast By 2028
October 26, 2021 | finance.yahoo.com
Cardiome Pharma Corp. Announces Approximately US$15.0 Million Bought Deal Financing
See More Headlines
Receive CRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiome Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2018
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRME
CUSIP
N/A
CIK
1036141
Web
www.cardiome.com
Phone
604-677-6905
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Optionable
Beta
N/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. William L. Hunter (Age 55)
    Pres, CEO & Director
  • Ms. Sheila M. Grant MBA
    Chief Operating Officer
  • Mr. David D. McMasters (Age 59)
    Gen. Counsel
  • Mr. Hugues Sachot
    Chief Commercial Officer
  • Mr. Justin A. Renz (Age 46)
    Chief Financial Officer

Key Competitors

View All Competitors

CRME Stock Analysis - Frequently Asked Questions

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Corp (NASDAQ:CRME) posted its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company earned $6.54 million during the quarter, compared to analyst estimates of $7.34 million.

What other stocks do shareholders of Cardiome Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiome Pharma investors own include Energy Transfer (ET), CBL & Associates Properties (CBL), Cornerstone Strategic Value Fund (CLM), Cornerstone Total Return Fund (CRF), SandRidge Permian Trust (PER), SunCoke Energy Partners (SXCP), Martin Midstream Partners (MMLP), Navios Maritime Midstream Partners (NAP), C3.ai (AI) and Government Properties Income Trust (GOV).

This page (NASDAQ:CRME) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
How Biden has already won 2024
Porter & Company
Urgent alert: open this for a huge profit potential
Timothy Sykes
My biggest AI fear
Paradigm Press